Vergara Daniela, López Olga, Sanhueza Claudia, Chávez-Aravena Catalina, Villagra José, Bustamante Mariela, Acevedo Francisca
Center of Excellence in Translational Medicine-Scientific Technological Bioresource Nucleus (CEMT-BIOREN), Faculty of Medicine, Universidad de La Frontera, Casilla 54-D, Temuco 4780000, Chile.
Department of Chemical and Surfactant Technology, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), C/Jordi Girona 18-26, 08034 Barcelona, Spain.
Pharmaceutics. 2023 Jul 9;15(7):1912. doi: 10.3390/pharmaceutics15071912.
A novel co-encapsulation system called bicosomes (bicelles within liposomes) has been developed to overcome the limitations associated with the topical application of curcumin (cur) and α-tocopherol (α-toc). The physicochemical properties and biological activity in vitro of bicosome systems were evaluated. Bicelles were prepared with DPPC, DHPC, cur, and α-toc (cur/α-toc-bicelles). Liposomal vesicles loading cur/α-toc-bicelles were prepared with Lipoid P-100 and cholesterol-forming cur/α-toc-bicosomes. Three cur/α-toc-bicosomes were evaluated using different total lipid percentages (12, 16, and 20% /). The results indicated that formulations manage to solubilize cur and α-toc in homogeneous bicelles < 20 nm, while the bicosomes reaches 303-420 nm depending on the total lipid percentage in the systems. Bicosomes demonstrated high-encapsulation efficiency (EE) for cur (56-77%) and α-toc (51-65%). The loading capacity (LC) for both antioxidant compounds was 52-67%. In addition, cur/α-toc-bicosomes decreased the lipid oxidation by 52% and increased the antioxidant activity by 60% compared to unloaded bicosomes. The cell viability of these cur/α-toc-bicosomes was >85% in fibroblasts (3T3L1/CL-173™) and ≥65% in keratinocytes (Ha-CaT) and proved to be hematologically compatible. The cur/α-toc-bicelles and cur/α-toc-bicosomes inhibited the growth of in a range between 33 and 76%. Our results propose bicosome systems as a novel carrier able to co-encapsulate, solubilize, protect, and improve the delivery performance of antioxidant molecules. The relevance of these findings is based on the synergistic antioxidant effect of its components, its biocompatibility, and its efficacy for dermal tissue treatment damaged by oxidative stress or by the presence of . However, further studies are needed to assess the efficacy and safety of cur/α-toc bicosomes in vitro and in vivo.
一种名为双囊体(脂质体内的双分子层)的新型共包封系统已被开发出来,以克服姜黄素(Cur)和α-生育酚(α-Toc)局部应用的局限性。对双囊体系统的理化性质和体外生物活性进行了评估。用二棕榈酰磷脂酰胆碱(DPPC)、二氢磷脂酰胆碱(DHPC)、Cur和α-Toc制备双分子层(Cur/α-Toc-双分子层)。用Lipoid P-100和胆固醇制备负载Cur/α-Toc-双分子层的脂质体囊泡,形成Cur/α-Toc-双囊体。使用不同的总脂质百分比(12%、16%和20%)评估了三种Cur/α-Toc-双囊体。结果表明,制剂成功地将Cur和α-Toc溶解在小于20 nm的均匀双分子层中,而双囊体的大小根据系统中的总脂质百分比在303-420 nm之间。双囊体对Cur(56-77%)和α-Toc(51-65%)表现出高包封率(EE)。两种抗氧化化合物的载药量(LC)为52-67%。此外,与未负载的双囊体相比,Cur/α-Toc-双囊体使脂质氧化降低了52%,抗氧化活性提高了60%。这些Cur/α-Toc-双囊体在成纤维细胞(3T3L1/CL-173™)中的细胞活力>85%,在角质形成细胞(Ha-CaT)中的细胞活力≥65%,并被证明具有血液相容性。Cur/α-Toc-双分子层和Cur/α-Toc-双囊体在33%至76%的范围内抑制了[具体内容缺失]的生长。我们的结果表明双囊体系统是一种新型载体,能够共包封、溶解、保护并改善抗氧化分子的递送性能。这些发现的相关性基于其成分的协同抗氧化作用、生物相容性以及对氧化应激或[具体内容缺失]存在所损伤的皮肤组织的治疗效果。然而,需要进一步研究来评估Cur/α-Toc双囊体在体外和体内的疗效和安全性。